Long-term follow-up of patients with anti-cyclic citrullinated peptide antibody-positive connective tissue disease: a retrospective observational study including information on the HLA-DRB1 allele and citrullination dependency

Background The anti-cyclic citrullinated peptide (CCP) antibody is a diagnostic biomarker of rheumatoid arthritis (RA). However, some non-RA connective tissue disease (CTD) patients also test positive for the anti-CCP antibody and, thus, may ultimately develop RA. We retrospectively investigated whether anti-CCP-positive non-RA CTD patients developed RA and attempted to identify factors that may differentiate RA-overlapping CTD from pure CTD. Methods In total, 842 CTD patients with a primary diagnosis that was not RA were selected from our CTD database as of December 2012. Anti-CCP antibody titers were obtained from a retrospective chart review or measured using stored sera. RA was diagnosed according to the 1987 revised American College of Rheumatology classification criteria. Thirty-three anti-CCP-positive non-RA CTD patients were retrospectively followed up for the development of RA. Bone erosions on the hands and feet were assessed by X-ray. Citrullination dependency was evaluated by an in-house ELISA, the HLA-DRB1 allele was typed, and the results obtained were then compared between RA-overlapping and non-RA anti-CCP-positive CTD patients. Results Two out of 33 anti-CCP-positive CTD patients (6.1%) developed RA during a mean follow-up period of 8.9 years. X-rays were examined in 27 out of the 33 patients, and only one (3.7%) showed bone erosions. The frequency of the HLA-DRB1 shared epitope (SE) and anti-CCP antibody titers were both significantly higher in anti-CCP-positive RA-overlapping CTD patients than in anti-CCP-positive non-RA CTD patients, while no significant differences were observed in citrullination dependency. Conclusions Anti-CCP-positive non-RA CTD patients rarely developed RA. HLA-DRB1 SE and anti-CCP antibody titers may facilitate the differentiation of RA-overlapping CTD from anti-CCP-positive non-RA CTD.Transplantation and autoimmunit

The characterization of anti-carbamylated protein antibodies in rheumatic diseases : isotype usage, avidity and molecular composition

The scope of this thesis is to describe the immunological characteristics and molecular composition of anti-CarP antibodies in rheumatoid arthritis, as well as the presence of anti-CarP antibodies in relation to bone erosions on diseases other than RA. This thesis is subdivided in three parts.Part 1: Characterisation of the anti-CarP antibody response in rheumatoid arthritisBoth ACPA and anti-CarP antibodies are present in RA.We describe the examination of the anti-CarP antibody response in RA by means of isotype and IgG-subclass usage in baseline serum samples of RA-patients as well as by means of the avidity of anti-CarP antibodies. Moreover, the anti-CarP IgG V-domain glycosylation was studied.Part 2: Possibilities for a mucosal origin of autoantibodies in rheumatoid arthritisSeveral lines of evidence obtained in the recent years indicate a role for mucosal surfaces in the development of auto-immune responses associated with RA. Therefore, we studied the molecular composition of RA associated IgA autoantibodies.Part 3: anti-CarP antibodies in other rheumatic diseases that can be characterized by bone erosionsBecause anti-CarP antibodies and ACPAs are also present in other clinical conditions than RA, we investigated their presence and association with bone erosions in Systemic Lupus Erythematosus and hand osteorthritis.LUMC / Geneeskund

Secretory form of rheumatoid arthritis-associated autoantibodies in serum are mainly of the IgM isotype, suggesting a continuous reactivation of autoantibody responses at mucosal surfaces

Pathophysiology and treatment of rheumatic disease

Presence of Autoantibodies in Erosive Hand Osteoarthritis and Association with Clinical Presentation

Transplantation and autoimmunit

THE ISOTYPE AND SUBCLASS DISTRIBUTION OF ANTI-CARBAMYLATED PROTEIN ANTIBODIES IN RHEUMATOID ARTHRITIS PATIENTS

Transplantation and autoimmunit

IgA Immune Complexes Induce Osteoclast-Mediated Bone Resorption

© Copyright © 2021 Breedveld, van Gool, van Delft, van der Laken, de Vries, Jansen and van Egmond.Objective: Autoantibodies are detected in most patients with rheumatoid arthritis (RA) and can be of the IgM, IgG or IgA subclass. Correlations between IgA autoantibodies and more severe disease activity have been previously reported, but the functional role of IgA autoantibodies in the pathogenesis of RA is ill understood. In this study, we explored the effect of IgA immune complexes on osteoclast mediated bone resorption. Methods: Anti-citrullinated peptide antibody (ACPA) and anti-carbamylated protein (anti-CarP) antibody levels of the IgA and IgG isotype and rheumatoid factor (RF) IgA were determined in synovial fluid (SF) of RA patients. Monocytes, neutrophils, and osteoclasts were stimulated with precipitated immune complexes from SF of RA patients or IgA- and IgG-coated beads. Activation was determined by neutrophil extracellular trap (NET) release, cytokine secretion, and bone resorption. Results: NET formation by neutrophils was enhanced by SF immune complexes compared to immune complexes from healthy or RA serum. Monocytes stimulated with isolated SF immune complexes released IL-6 and IL-8, which correlated with the levels of ACPA IgA levels in SF. Osteoclasts cultured in the presence of supernatant of IgA-activated monocytes resorbed significantly more bone compared to osteoclasts that were cultured in supernatant of IgG-activated monocytes (p=0.0233). Osteoclasts expressed the Fc receptor for IgA (FcαRI; CD89) and Fc gamma receptors. IgA-activated osteoclasts however produced significantly increased levels of IL-6 (p<0.0001) and IL-8 (p=0.0007) compared to IgG-activated osteoclasts. Both IL-6 (p=0.03) and IL-8 (p=0.0054) significantly enhanced bone resorption by osteoclasts. Conclusion: IgA autoantibodies induce release of IL-6 and IL-8 by immune cells as well as osteoclasts, which enhances bone resorption by osteoclasts. We anticipate that this will result in more severe disease activity in RA patients. Targeting IgA-FcαRI interactions therefore represents a promising novel therapeutic strategy for RA patients with IgA autoantibodies

The risk of individual autoantibodies, autoantibody combinations and levels for arthritis development in clinically suspect arthralgia

Pathophysiology and treatment of rheumatic disease

The anti-carbamylated protein antibody response is of overall low avidity despite extensive isotype switching

Transplantation and autoimmunit

The isotype and IgG subclass distribution of anti-carbamylated protein antibodies in rheumatoid arthritis patients

Pathophysiology and treatment of rheumatic disease